Literature DB >> 21969285

Ceftriaxone-induced hemolysis in a child with Lyme arthritis: a case for antimicrobial stewardship.

Sarah R Boggs1, Kenji M Cunnion, Reem H Raafat.   

Abstract

Guidelines for the treatment of Lyme arthritis were published by the Infectious Diseases Society of America in 2006 and recommended oral doxycycline for initial therapy. We report here the case of a young girl treated with intravenous ceftriaxone who subsequently developed drug-induced autoimmune hemolytic anemia and renal failure. Her severe sequelae highlight the importance of antimicrobial stewardship. We review here the goals of antimicrobial stewardship and several strategies for achieving them. In addition, we briefly discuss the rare adverse drug event experienced by our patient.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21969285     DOI: 10.1542/peds.2010-1570

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  4 in total

1.  Rapid Antimicrobial Susceptibility Testing Using Forward Laser Light Scatter Technology.

Authors:  Randall T Hayden; Lani K Clinton; Carolyn Hewitt; Terri Koyamatsu; Yilun Sun; Ginger Jamison; Rosalie Perkins; Li Tang; Stanley Pounds; Matthew J Bankowski
Journal:  J Clin Microbiol       Date:  2016-08-24       Impact factor: 5.948

Review 2.  Outpatient parenteral antimicrobial therapy with ceftriaxone, a review.

Authors:  Christopher J A Duncan; David A Barr; R Andrew Seaton
Journal:  Int J Clin Pharm       Date:  2012-04-17

3.  Aminoglycosides induce fragility of human red cell membrane: an in vitro study.

Authors:  Abdulkadir A Alnakshbandi
Journal:  Indian J Pharmacol       Date:  2015 Jan-Feb       Impact factor: 1.200

4.  Severe delayed autoimmune haemolytic anaemia following artesunate administration in severe malaria: a case report.

Authors:  Loic Raffray; Marie-Catherine Receveur; Mathilde Beguet; Pierre Lauroua; Thierry Pistone; Denis Malvy
Journal:  Malar J       Date:  2014-10-11       Impact factor: 2.979

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.